Short Interest to Follow: Benitec Biopharma Limited Ads (NASDAQ:BNTC) Has Decline in Shorts

November 28, 2016 - By Dolores Ford   ·   0 Comments

Short Interest to Follow: Benitec Biopharma Limited Ads (NASDAQ:BNTC) Has Decline in Shorts

The stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered a decrease of 18.03% in short interest. BNTC’s total short interest was 15,000 shares in November as published by FINRA. Its down 18.03% from 18,300 shares, reported previously. With 6,700 shares average volume, it will take short sellers 2 days to cover their BNTC’s short positions. The short interest to Benitec Biopharma Limited Ads’s float is 0.27%. The stock closed at $1.55 during the last session. It is down 5.49% since April 25, 2016 and is downtrending. It has underperformed by 11.50% the S&P500.

Benitec Biopharma Limited is a biotechnology company. The company has a market cap of $13.63 million. The Firm is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property ; development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. It currently has negative earnings. The Company’s In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.

More notable recent Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on October 31, 2014, also Seekingalpha.com with their article: “Benitec’s DdRNAi Targeting Fight Against HIV” published on August 13, 2014, Benzinga.com published: “Arbutus Biopharma Taken Off Of Chardan’s Sell List” on June 16, 2016. More interesting news about Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) were released by: Barrons.com and their article: “Anglo American Mines for Profits” published on April 25, 2015 as well as Reuters.com‘s news article titled: “Benitec Biopharma says commenced strategic engagement with Nantventures” with publication date: October 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>